BRCA mutations are also present in numerous other cancers such as lung, endothelial, and Acute myeloid leukemia (reviewed in PMID: 33015058), but were not reviewed due to a lack of FDA-approved PARP inhibitors for therapy. The gene discussed is PARP1; the disease is cancer.